These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 26205827)

  • 1. Prophylactic liraglutide treatment prevents amyloid plaque deposition, chronic inflammation and memory impairment in APP/PS1 mice.
    McClean PL; Jalewa J; Hölscher C
    Behav Brain Res; 2015 Oct; 293():96-106. PubMed ID: 26205827
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liraglutide can reverse memory impairment, synaptic loss and reduce plaque load in aged APP/PS1 mice, a model of Alzheimer's disease.
    McClean PL; Hölscher C
    Neuropharmacology; 2014 Jan; 76 Pt A():57-67. PubMed ID: 23973293
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer's disease.
    McClean PL; Parthsarathy V; Faivre E; Hölscher C
    J Neurosci; 2011 Apr; 31(17):6587-94. PubMed ID: 21525299
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lixisenatide, a drug developed to treat type 2 diabetes, shows neuroprotective effects in a mouse model of Alzheimer's disease.
    McClean PL; Hölscher C
    Neuropharmacology; 2014 Nov; 86():241-58. PubMed ID: 25107586
    [TBL] [Abstract][Full Text] [Related]  

  • 5. D-Ala2GIP facilitated synaptic plasticity and reduces plaque load in aged wild type mice and in an Alzheimer's disease mouse model.
    Faivre E; Hölscher C
    J Alzheimers Dis; 2013; 35(2):267-83. PubMed ID: 23568101
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-Term Treatment with Liraglutide, a Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist, Has No Effect on β-Amyloid Plaque Load in Two Transgenic APP/PS1 Mouse Models of Alzheimer's Disease.
    Hansen HH; Fabricius K; Barkholt P; Kongsbak-Wismann P; Schlumberger C; Jelsing J; Terwel D; Termont A; Pyke C; Knudsen LB; Vrang N
    PLoS One; 2016; 11(7):e0158205. PubMed ID: 27421117
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Colivelin Ameliorates Impairments in Cognitive Behaviors and Synaptic Plasticity in APP/PS1 Transgenic Mice.
    Wu M; Shi H; He Y; Yuan L; Qu X; Zhang J; Wang Z; Cai H; Qi J
    J Alzheimers Dis; 2017; 59(3):1067-1078. PubMed ID: 28731445
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The incretin analogue D-Ala2GIP reduces plaque load, astrogliosis and oxidative stress in an APP/PS1 mouse model of Alzheimer's disease.
    Duffy AM; Hölscher C
    Neuroscience; 2013 Jan; 228():294-300. PubMed ID: 23103794
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Donepezil improves learning and memory deficits in APP/PS1 mice by inhibition of microglial activation.
    Guo HB; Cheng YF; Wu JG; Wang CM; Wang HT; Zhang C; Qiu ZK; Xu JP
    Neuroscience; 2015 Apr; 290():530-42. PubMed ID: 25662507
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The GLP-1 Receptor Agonist Liraglutide Improves Memory Function and Increases Hippocampal CA1 Neuronal Numbers in a Senescence-Accelerated Mouse Model of Alzheimer's Disease.
    Hansen HH; Fabricius K; Barkholt P; Niehoff ML; Morley JE; Jelsing J; Pyke C; Knudsen LB; Farr SA; Vrang N
    J Alzheimers Dis; 2015; 46(4):877-88. PubMed ID: 25869785
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treadmill exercise enhances synaptic plasticity, but does not alter β-amyloid deposition in hippocampi of aged APP/PS1 transgenic mice.
    Zhao G; Liu HL; Zhang H; Tong XJ
    Neuroscience; 2015 Jul; 298():357-66. PubMed ID: 25917310
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chronic treatment with the α2-adrenoceptor antagonist fluparoxan prevents age-related deficits in spatial working memory in APP×PS1 transgenic mice without altering β-amyloid plaque load or astrocytosis.
    Scullion GA; Kendall DA; Marsden CA; Sunter D; Pardon MC
    Neuropharmacology; 2011; 60(2-3):223-34. PubMed ID: 20850464
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metformin treatment prevents amyloid plaque deposition and memory impairment in APP/PS1 mice.
    Ou Z; Kong X; Sun X; He X; Zhang L; Gong Z; Huang J; Xu B; Long D; Li J; Li Q; Xu L; Xuan A
    Brain Behav Immun; 2018 Mar; 69():351-363. PubMed ID: 29253574
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of focal brain injury on beta-amyloid plaque deposition, inflammation and synapses in the APP/PS1 mouse model of Alzheimer's disease.
    Collins JM; King AE; Woodhouse A; Kirkcaldie MT; Vickers JC
    Exp Neurol; 2015 May; 267():219-29. PubMed ID: 25747037
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glucose tolerance and insulin sensitivity are impaired in APP/PS1 transgenic mice prior to amyloid plaque pathogenesis and cognitive decline.
    Macklin L; Griffith CM; Cai Y; Rose GM; Yan XX; Patrylo PR
    Exp Gerontol; 2017 Feb; 88():9-18. PubMed ID: 28025127
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Val(8)GLP-1 rescues synaptic plasticity and reduces dense core plaques in APP/PS1 mice.
    Gengler S; McClean PL; McCurtin R; Gault VA; Hölscher C
    Neurobiol Aging; 2012 Feb; 33(2):265-76. PubMed ID: 20359773
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nitration of tyrosine 10 critically enhances amyloid β aggregation and plaque formation.
    Kummer MP; Hermes M; Delekarte A; Hammerschmidt T; Kumar S; Terwel D; Walter J; Pape HC; König S; Roeber S; Jessen F; Klockgether T; Korte M; Heneka MT
    Neuron; 2011 Sep; 71(5):833-44. PubMed ID: 21903077
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evidence for the involvement of calbindin D28k in the presenilin 1 model of Alzheimer's disease.
    Odero GL; Oikawa K; Glazner KA; Schapansky J; Grossman D; Thiessen JD; Motnenko A; Ge N; Martin M; Glazner GW; Albensi BC
    Neuroscience; 2010 Aug; 169(1):532-43. PubMed ID: 20399254
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liraglutide and a lipidized analog of prolactin-releasing peptide show neuroprotective effects in a mouse model of β-amyloid pathology.
    Holubová M; Hrubá L; Popelová A; Bencze M; Pražienková V; Gengler S; Kratochvílová H; Haluzík M; Železná B; Kuneš J; Hölscher C; Maletínská L
    Neuropharmacology; 2019 Jan; 144():377-387. PubMed ID: 30428311
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Normal induction but accelerated decay of LTP in APP + PS1 transgenic mice.
    Gureviciene I; Ikonen S; Gurevicius K; Sarkaki A; van Groen T; Pussinen R; Ylinen A; Tanila H
    Neurobiol Dis; 2004 Mar; 15(2):188-95. PubMed ID: 15006688
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.